CN106604726A - 用于治疗史密斯‑马吉利综合征的他司美琼 - Google Patents

用于治疗史密斯‑马吉利综合征的他司美琼 Download PDF

Info

Publication number
CN106604726A
CN106604726A CN201580046852.7A CN201580046852A CN106604726A CN 106604726 A CN106604726 A CN 106604726A CN 201580046852 A CN201580046852 A CN 201580046852A CN 106604726 A CN106604726 A CN 106604726A
Authority
CN
China
Prior art keywords
melatonin
methods
individual
simeiqiong
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580046852.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·拉夫当
M·H·波利梅洛伯罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106604726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority to CN202310255914.1A priority Critical patent/CN116098887A/zh
Publication of CN106604726A publication Critical patent/CN106604726A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Processing Of Solid Wastes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Steroid Compounds (AREA)
CN201580046852.7A 2014-09-02 2015-08-29 用于治疗史密斯‑马吉利综合征的他司美琼 Pending CN106604726A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310255914.1A CN116098887A (zh) 2014-09-02 2015-08-29 用于治疗史密斯-马吉利综合征的他司美琼

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310255914.1A Division CN116098887A (zh) 2014-09-02 2015-08-29 用于治疗史密斯-马吉利综合征的他司美琼

Publications (1)

Publication Number Publication Date
CN106604726A true CN106604726A (zh) 2017-04-26

Family

ID=54147267

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580046852.7A Pending CN106604726A (zh) 2014-09-02 2015-08-29 用于治疗史密斯‑马吉利综合征的他司美琼
CN202310255914.1A Pending CN116098887A (zh) 2014-09-02 2015-08-29 用于治疗史密斯-马吉利综合征的他司美琼

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310255914.1A Pending CN116098887A (zh) 2014-09-02 2015-08-29 用于治疗史密斯-马吉利综合征的他司美琼

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP3188727B1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20240015729A (enExample)
CN (2) CN106604726A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA2957588C (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
AU2015312252B2 (en) * 2014-09-02 2020-07-02 Vanda Pharmaceuticals Inc. Tasimelteon for treating Smith-Magenis Syndrome
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
KR20210060489A (ko) * 2018-09-12 2021-05-26 반다 파마슈티칼즈, 인코퍼레이티드. 수면 또는 수면 후 거동 개선
CN114727978A (zh) 2019-12-13 2022-07-08 万达制药公司 液体他司美琼制剂及其使用方法
TWI891877B (zh) 2020-08-27 2025-08-01 日商友華股份有限公司 檢查裝置
US20250339398A1 (en) * 2021-09-14 2025-11-06 Vanda Pharmaceuticals Inc. Treatment of sleep distrubances in autism spectrum disorder patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4290765B2 (ja) 1996-12-10 2009-07-08 ブリストル−マイヤーズ スクイブ カンパニー ベンゾジオキソール、ベンゾフラン、ジヒドロベンゾフランおよびベンゾジオキサンメラトニン作用薬
WO2005063240A1 (en) 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
WO2013112949A2 (en) * 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
AU2015312252B2 (en) * 2014-09-02 2020-07-02 Vanda Pharmaceuticals Inc. Tasimelteon for treating Smith-Magenis Syndrome
CN114727978A (zh) * 2019-12-13 2022-07-08 万达制药公司 液体他司美琼制剂及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
RUDIGER HARDELAND: "New approches in the management of insomnia: weighing the advantage of prolonged-release melatonin and synthetic melatoninergic agnists", 《NEUROPSYCHIATRIC DISEASE AND TREATMENT》 *
SANCHEZ-BARCELO EJ等: "Clinical Uses of Melatonin: Evaluation of Human Trials", 《CURRENT MEDICINAL CHEMISTRY》 *
VAN THILLO A ET AL: "sleep disturbance in smith-magenis syndrome: treatment with melatonin and beta-adrenergic antagonists", 《TIJDSCHRIFT VOOR PSYCHIATRIE》 *
张翼: "FDA批准褪黑素受体激动剂他司美琼(Tasimelteon)治疗盲人非24小时睡眠觉醒障碍", 《药品评价》 *
黄培新等: "《神经科专病中医临床诊治》", 31 October 2013, 人民卫生出版社 *

Also Published As

Publication number Publication date
US20220133681A1 (en) 2022-05-05
EP3188727A1 (en) 2017-07-12
US10653665B2 (en) 2020-05-19
JP7132277B2 (ja) 2022-09-06
US20240293355A1 (en) 2024-09-05
US20190105297A1 (en) 2019-04-11
JP2022078291A (ja) 2022-05-24
HUE061051T2 (hu) 2023-05-28
PT3188727T (pt) 2023-01-30
JP7252390B2 (ja) 2023-04-04
AU2020239640B2 (en) 2020-11-05
AU2020239640A1 (en) 2020-10-15
AU2015312252B2 (en) 2020-07-02
FI3188727T3 (fi) 2023-02-20
CN116098887A (zh) 2023-05-12
US11266622B2 (en) 2022-03-08
KR20170048541A (ko) 2017-05-08
MX386150B (es) 2025-03-18
BR112017003644A2 (pt) 2017-11-28
JP2020143159A (ja) 2020-09-10
EP4137129A1 (en) 2023-02-22
NZ729901A (en) 2020-09-25
JP6903571B2 (ja) 2021-07-14
JP2017526693A (ja) 2017-09-14
EP3188727B1 (en) 2022-11-09
CA3124872A1 (en) 2016-03-10
AU2015312252A1 (en) 2017-03-30
HRP20230070T1 (hr) 2023-03-17
NZ765911A (en) 2023-08-25
CA2957588A1 (en) 2016-03-10
US20200237712A1 (en) 2020-07-30
CA2957588C (en) 2021-08-31
KR20240015729A (ko) 2024-02-05
SI3188727T1 (sl) 2023-03-31
DK3188727T3 (da) 2023-02-06
US20170239210A1 (en) 2017-08-24
MX2017002796A (es) 2017-06-09
US10179119B2 (en) 2019-01-15
ES2936833T3 (es) 2023-03-22
WO2016036619A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
JP7252390B2 (ja) スミス‐マゲニス症候群を治療するためのタシメルテオン
EA015256B1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
CA2949910C (en) Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
AU2011376333A1 (en) Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
WO2025188976A1 (en) Fused amino pyrimidine compounds for treatment of neurodegenerative disorders
Hendrix et al. Low-Frequency Oscillations in the Cerebellar Cortex of

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170426